Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO) (INDIGO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04065529|
Recruitment Status : Not yet recruiting
First Posted : August 22, 2019
Last Update Posted : August 27, 2019
|Condition or disease||Intervention/treatment||Phase|
|Diarrhea||Combination Product: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation Combination Product: placebo + ORS + Zinc supplementation||Phase 3|
Hide Detailed Description
To evaluate the safety, global efficacy and rapidity of action of GT in children with acute gastroenteritis taking ORS solution.
Study centers/ settings: The recruitment will take place in public health facilities in Senegal.
Proposed site is the Niakhar Center IRD BP 1386 Hann Mariste, Dakar-Senegal) with the health center of Niakhar as satellite site. More sites can be opened at the discretion of the Sponsor if required
Study design and type:
Interventional, randomized, controlled, double blind, multicenter phase III clinical trial.
Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation versus (vs.) placebo + ORS + Zinc supplementation.
Investigational Product: GELATIN TANNATE (GT):
- Children below 3 years of age: One sachet every 6 hours
- Children from 3 to 14 years of age: 2 sachets every 6 hours. All patients will take ORS solution according to 2014 European recommendations, and Zinc supplementation.
Placebo. The dose regimen and mode of administration will be similar as the investigational product.
Number of patients planned:
150 patients, randomized in 1:1 basis (75 in each arm).
Children eligible for the trial must fulfil ALL of the following criteria:
- AGE defined as a change in stool consistency to loose or liquid form (according to the Bristol Stool Form (BSF) scale ≥ 6 or, the Brussels Infant and Toddler Stool Scale (BITSS) =4 in the case of infants ≤ 3 years (see Annex 1) and/or an increase in the frequency of evacuations (typically ≥3 in 24 h),
- AGE lasting between 1 day and 2 days;
- Children from 3 months old
- Children up to 14 years old;
- Written informed consent form signed by parents or legal guardians must be provided to caregivers.
- Subject willing and able to comply with study restrictions and willing to return to the health center and to perform the follow-up evaluation as specified in the protocol.
Non-inclusion criteria: In order to participate in this study, all subjects must meet NONE of the following exclusion criteria:
- Use of antibiotics, diosmectite, probiotics, racecadotril, loperamide or zinc (including zinc containing ORS) within a week prior to enrolment
- Chronic diarrheal gastrointestinal disease (eg, inflammatory bowel diseases, cystic fibrosis, coeliac disease, food allergy)
- Signs of malnutrition according to the opinion of the investigator (weight/height under 3rd z score as per World Health Organization [WHO] Child Growth Standards)
- Subject who previously entered in a clinical study within the past 30 days.
- Pregnancy and suspected Pregnancy
Study duration: 7 days including 5 days of treatment; follow up at Day 7.
The primary outcome will be the duration of diarrhea, defined as the time between start of diarrhea and the normalization of stool consistency according to the BSF or BITSS (in BSF scale, =3 or =4; in BITSS, =2), or/and the time until the normalization of the number of stools (compared with the period before the onset of diarrhea), and the presence of normal stools for 48 h.
A subgroup analysis will be performed with patients for whom the cause of the diarrhea is not parasitic.
- Stool Decrease Index (SDI)
- Time resolution of diarrhea from start of treatment
- Need for intravenous rehydration
- Number of watery stools per day
- Weight gain
- Recurrence of diarrhea (48 h after intervention)
- Severity of diarrhea according to Vesikari scale
- Use of concomitant medications.
- Adverse events (AEs)
Significant decrease of duration of diarrhea with the Gelatin Tannate plus ORS plus zinc than placebo+ ORS +zinc
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Interventional, randomized, controlled, double blind, multicenter phase III clinical trial.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Efficacite et Innocuite du Tannate de Gelatine Dans le Traitement de la Diarrhee aiguë de l'Enfant. Une Etude Randomisee, Controlee, en Double Aveugle (INDIGO)|
|Estimated Study Start Date :||August 29, 2019|
|Estimated Primary Completion Date :||February 28, 2020|
|Estimated Study Completion Date :||March 31, 2020|
Experimental: Gelatin tannate (GT)
Gelatin tannate (GT)
Combination Product: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
Placebo Comparator: Placebo
Combination Product: placebo + ORS + Zinc supplementation
placebo + ORS + Zinc supplementation
- Duration of diarrhea [ Time Frame: 48 hours ]Duration of diarrhea, defined as the time between start of diarrhea and the normalization of stool consistency according to the BSF or BITSS (in BSF scale, =3 or =4; in BITSS, =2), or/and the time until the normalization of the number of stools (compared with the period before the onset of diarrhea), and the presence of normal stools for 48 h.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04065529
|Contact: Issatou B DIALLOemail@example.com|
|Contact: Principal Investigatorfirstname.lastname@example.org|
|Niakhar Center IRD||Not yet recruiting|
|Dakar, Senegal, 18524|
|Contact: Aldiouma Diallo, MS email@example.com|
|Sub-Investigator: El Hadj Ba|
|Sub-Investigator: Assane Diouf|
|Principal Investigator:||Aldiouma Diallo, MS||IRD Senegal (Niakhar Center IRD BP 1386 Hann Mariste, CP 18524 Dakar. Sénégal.|
|Study Director:||Javier Xllop||Noventure SL|